research use only
Cat.No.S5939
|
In vitro |
DMSO
: 72 mg/mL
(200.97 mM)
Ethanol : 7 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 358.26 | Formula | C16H21Cl2N3O2
|
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 16506-27-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | SDX105 | SMILES | CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O | ||
Read more about storage stability stock solution CAS number SMILES
(data from https://clinicaltrials.gov, updated on 2026-02-13)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06191887 | RECRUITING | B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia |
Mayo Clinic |
2024-03-18 | PHASE1 |
| NCT06191744 | ACTIVE_NOT_RECRUITING | Follicular Lymphoma (FL) |
Genmab |
2024-02-05 | PHASE3 |
| NCT07634471 | RECRUITING | Follicular Lymphoma |
Merck Sharp & Dohme LLC |
2026-06-22 | PHASE2; PHASE3 |
| NCT06313996 | WITHDRAWN | Relapsed or Refractory Follicular Lymphoma |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2024-03-29 | PHASE3 |
| NCT06205290 | WITHDRAWN | Leukemia, Lymphocytic, Chronic, B-Cell |
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company |
2024-01-16 | PHASE3 |
| NCT06363994 | RECRUITING | Mantle Cell Lymphoma |
InnoCare Pharma Inc. |
2024-05-29 | PHASE3 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.